|
|
|
|
|
|
|
|
|
|
Blogger's Note: the risk of leukemia as a secondary primary after treatment with Melphalan is not 'new' news; melphalan is not the only drug implicated in secondary chemotherapy-induced primaries
~~~~~~~~~~~~
Risk of leukemia after cancer chemotherapy persists"....A similar decline in risk was observed among ovarian cancer patients, possibly linked to a shift in ovarian cancer chemotherapy treatment in the 1970s from melphalan, a type of chemotherapy that has been shown to trigger leukemia, to a less toxic platinum-based chemotherapy....
" "Future studies should identify patients at the highest risk of tAML so that the risks can be weighed against the benefits of chemotherapy, particularly for cancers with favorable long-term survival," said Dr. Morton. "Further research is also warranted to assess the risks associated with new targeted and immunomodulatory agents by including secondary malignancies such as tAML as endpoints in prospective clinical studies of new agents or new uses of standard agents."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.